Log in to save to my catalogue

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f7c6a9ff87e544acbdd02715c577e12b

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

About this item

Full title

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2024-03, Vol.15 (1), p.2280-2280, Article 2280

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 and the potential of DC-based therapies in tumors carrying varied levels of bona-fide neoantigens (neoAgs) remain unclear. Here we develop a hypermutate...

Alternative Titles

Full title

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_f7c6a9ff87e544acbdd02715c577e12b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f7c6a9ff87e544acbdd02715c577e12b

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-024-46685-y

How to access this item